Avanir Pharmaceuticals Inc., of Aliso Viejo, Calif., said results from TARGET, its pivotal phase III study of AVP-825 22 mg, published in the January 2015 issue of Headache, show that the investigational drug-device combo – low-dose sumatripan delivered intranasally using the Breath Powered technology – resulted in relief of moderate or severe migraine headache as quickly as 15 minutes (19.4 percent AVP-825 vs. 14.4 percent placebo device).